Final Program
4njPuP
4njPuP
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
48 SUNDAY • MAY 15<br />
P14<br />
P15<br />
P16<br />
P17<br />
P18<br />
Facilitator:<br />
P19<br />
P20<br />
P21<br />
P22<br />
P23<br />
P24<br />
P25<br />
Anti-IgE Monoclonal Antibody Therapy as an Alternative for<br />
the Treatment of Occupational Asthma Caused by Exposure to<br />
Low Molecular Weight Agents/M.-J. Cruz, M. Olle-Monge, J.<br />
Yllera-Retegui, M.-D. Untoria-Corral, D. Alvarez-Simon, X. Munoz,<br />
Barcelona, Spain, p.A1309<br />
Predictors of Inhaled Corticosteroid Reduction Failure in Adult<br />
Asthmatics/J.C. Cardet, T.S. King, L.B. Bacharier, T.F. Carr, V.M.<br />
Chinchilli, C.D. Codispoti, R.M. Dunn, F. Holguin, K.F. Nelson, V.E.<br />
Ortega, M. Peters, S. Ramratnam, M.E. Wechsler, E. Israel,<br />
Boston, MA, p.A1310<br />
Knowledge of Risks of Asthma and Its Treatments Amongst<br />
Healthcare Professionals: A Questionnaire-Based Survey/A.<br />
Rameh, J. Blakey, Liverpool, United Kingdom, p.A1311<br />
Serum Periostin Level May Predict Asthma Exacerbation After<br />
Stepping Down Formoterol/Budesonide Combination Therapy<br />
in Adult Asthma/H. Nagase, T. Shirai, T. Kawayama, H. Inoue, S.<br />
Sato, K. Asano, K. Izuhara, H. Kume, Tokyo, Japan, p.A1312<br />
Characteristic Features of Late-Onset Hypereosinophilic Asthma/<br />
M. Toyoshima, Y. Kamiya, T. Suda, Hamamatsu, Japan, p.A1313<br />
N. Miyahara, MD, PhD, Okayama, Japan<br />
IL-13 Decreases M3R Expression in the Human Airway,<br />
Reducing the Effect of Tiotropium on Mucin Production/K.<br />
Komiya, S. Kawano, I. Suzaki, T. Akaba, J.L. Bradley, B.K. Rubin,<br />
Richmond, VA, p.A1314<br />
Mechanism of Reduced Glucocorticoid Sensitivity in Human<br />
Pulmonary Epithelial Cells: Implications for Regulation by<br />
Interferon Regulatory Factor (IRF1)/S.V. Shah, R. Newton,<br />
Calgary, Canada, p.A1315<br />
STRETTO: Design and Baseline Characteristics of a Phase III,<br />
Double-Blind, Placebo-Controlled Study to Assess the Efficacy<br />
and Safety of Lebrikizumab in Adult Patients with<br />
Mild-to-Moderate Asthma/K. Yen, C.T.J. Holweg, J.<br />
Anzures-Cabrera, C. Martin, J. Olsson, J.G. Matthews, South San<br />
Francisco, CA, p.A1316<br />
Clinical Symptom Burden in Severe Asthma One Year After<br />
Completion of Bronchial Thermoplasty/M. Curtiss, Y. Wang, D.<br />
Zhi, F. Wang, J.T. Anderson, M.T. Dransfield, J.S. Deshane, J.<br />
Trevor, Birmingham, AL, p.A1317<br />
LAVOLTA I and II: Design and Baseline Characteristics of Two<br />
Phase III, Randomized, Double-Blind, Placebo-Controlled<br />
Studies to Assess the Efficacy and Safety of Lebrikizumab in<br />
Adult Patients with Uncontrolled Asthma/N.A. Hanania, P.<br />
Korenblat, K.R. Chapman, E.D. Bateman, P. Kopecky, P. Paggiaro,<br />
A. Yokoyama, J. Olsson, S. Gray, C.T.J. Holweg, M. Eisner, J.G.<br />
Matthews, Houston, TX, p.A1318<br />
Topical NSAID and NERD Phenotype Asthma Control/A.A. Hsu,<br />
Singapore, Singapore, p.A1319<br />
Clinical Endpoint Bioequivalence Study of Salmeterol<br />
Xinafoate (SX)/Fluticasone Propionate (FP) Combination Brand<br />
and Generic Candidate Products in Patients with Asthma/M.<br />
Longphre, K. Beasley, E. Burmeister Getz, R. Fuller, Berkeley, CA,<br />
p.A1320<br />
P26<br />
Facilitator:<br />
P27<br />
P28<br />
P29<br />
P30<br />
P31<br />
P32<br />
P33<br />
P34<br />
P35<br />
P36<br />
P37<br />
Plasma Inhaled Fluticasone Levels and Their Clinical<br />
Implications in Asthma/A. Matsubara, A. Takahashi, E.<br />
Yamaguchi, N. Yokoe, I. Okajima, K. Kosaka, M. Nishimura, H.<br />
Tanaka, N. Asai, A. Kubo, Nagakute, Japan, p.A1321<br />
J.G. Zangrilli, MD, Philadelphia, PA<br />
Step Down Strategy; Can LTRA Be Withdrawn Safely From<br />
Combination Therapy with Medium to High Dose of ICS/LABA,<br />
Tiotropium Bromide and LTRA in Severe Asthmatics?/M. Hojo,<br />
M. Iikura, M. Suzuki, H. Sugiyama, Tokyo, Japan, p.A1322<br />
Safety and Efficacy of Vilanterol and Fluticasone<br />
furoate/Vilanterol in the Treatment of Asthma: A Systematic<br />
Review and Meta-Analysis/H. Zhou, C. Liu, Chengdu, China,<br />
p.A1323<br />
Extraction of Membrane Cholesterol as a Potential New<br />
Therapeutic Mechanism in Asthma/G. Dufour, N. Rocks, A.<br />
Duyckaerts, C. Gerard, M.-P. Mingeot-Leclercq, B. Evrard, D.<br />
Cataldo, Liege, Belgium, p.A1324<br />
Chinese Herbs for Acute Asthma: A Multi-Center, Randomized,<br />
Double-Blind, Placebo-Controlled Trial/G. Wang, Chengdu,<br />
China, p.A1325<br />
Safety and Tolerability of AZD1419, an Inhaled<br />
Oligonucleotide-Based Toll-Like Receptor 9 Agonist in Healthy<br />
Volunteers: A Potential New Therapy for Asthma/S. Jackson, S.<br />
Floettmann, A. Candia, C. Wong, S. Delaney, D. Keeling, R. Fuhr,<br />
R.L. Coffman, Berkeley, CA, p.A1326<br />
Efficacy of the Anti-IgE Monoclonal Antibody Omalizumab in<br />
Patients with Severe Asthma Complicated with Eosinophilic<br />
Otitis Media/E. Tagaya, R. Mizobuchi, A. Kubo, K. Hara, K.<br />
Takeyama, M. Kondo, J. Tamaoki, Tokyo, Japan, p.A1327<br />
Interleukin 17 (IL-17) Targeting Therapy in Asthma/M.<br />
Mahdavian, A. Ferrell, S. Asghari, Y. Yi, S.D. Aaron, Ottawa,<br />
Canada, p.A1328<br />
A Novel Inhaled Non-Steroidal Modulator of Inflammation for<br />
the Control of Asthma; AZD7594/C.K. Mardh, W. Russell, M.<br />
Gustavsson, N. Kurian, A.-H. Jansson, A. Smailagic, K. Edman,<br />
Molndal, Sweden, p.A1329<br />
Assessment of Asthma Control in Adults Using Extrafine<br />
Inhaled Beclomethasone/Formoterol Combination as<br />
Maintenance Therapy or Maintenance and Reliever Therapy: A<br />
Multicentre Prospective Observational Study/R. Pawliczak, B.<br />
Rogala, T. Debowski, Lodz, Poland, p.A7769<br />
RPL554, a First-In-Class Dual Phosphodiesterase (PDE)3/4<br />
Inhibitor, Is Equi-Effective as a Bronchodilator to Maximal<br />
Doses of Salbutamol in Asthmatics but with Fewer Adverse<br />
Events/L. Bjermer, J. Stewart, K.H. Abbott-Banner, K. Newman,<br />
Lund, Sweden, p.A7770<br />
A Potential Mechanism for Steroid Resistance in Severe<br />
Asthma/M. Gauthier, T. Oriss, M. Raundhal, C. Morse, S.E.<br />
Wenzel, P. Ray, A. Ray, Pittsburgh, PA, p.A7771<br />
ATS 2016 • San Francisco